With the recent Abbvie agreement, Momenta will be able to commercialise M923 in the United States, pending regulatory approval, as early as
November 20, 2023. The company has decided to delay the filing of the BLA, which is likely to reduce programme costs in 2019 without delaying M923's potential US market entry.